This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Dec;30(8):715-7.

doi: 10.1016/j.ctrv.2004.09.003.

Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer

No authors listed

PMID: 15541582
DOI: 10.1016/j.ctrv.2004.09.003

Comment

Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer

No authors listed. Cancer Treat Rev. 2004 Dec.

. 2004 Dec;30(8):715-7.

doi: 10.1016/j.ctrv.2004.09.003.

PMID: 15541582
DOI: 10.1016/j.ctrv.2004.09.003

No abstract available

PubMed Disclaimer

Comment on

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Hurwitz H, et al. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691. N Engl J Med. 2004. PMID: 15175435 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science